EDITORIAL COMMENT

Application of robot-assisted surgery has progressed with its use in the pelvis especially for radical cystectomy and hysterectomy. Despite this advance, the average patient undergoing robot-assisted radical cystectomy is older, has multiple comorbid conditions and potential for metastatic disease which needs to be addressed with thorough oncologic diligence. Fairey et al\(^1\) in their retrospective analysis of 314 patients found that severe medical comorbidity was associated with an increased 90 day mortality and risk of postoperative complication. Megwalu II et al\(^2\) evaluated 675 patients and revealed that comorbidity was an independent predictor of overall survival. This paper brings to light a critical component observed in patients who are surgical candidates for advanced localized bladder cancer. However, robot-assisted radical cystectomy should be cautiously introduced at centers which have already established their robot-assisted surgical programs. Extensive experience in robot-assisted radical prostatectomy and a significant background in open oncologic surgery are required to manage the burden of this lethal disease.

References


Khurshid A Guru, MD
Director, Robotic Surgery
Roswell Park Cancer Institute
Clinical Assistant Professor of Urology
University at Buffalo
Buffalo, New York, USA